Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

Know AML will mark AML World Awareness Day on Tuesday April 21, 2026, uniting patients, caregivers, societies, and the wider community to raise awareness of acute myeloid leukemia (AML). Many people ...

Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, ...

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...

Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.

The 17th annual Battle of the Buffalo returned to Big Spring Park Saturday, with 16 restaurants competing to honor a ...

Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...